IP Library › Granted Patent US 12680084
Granted Patent B2
US 12680084 · App. 17/793,150 · Granted Jul 14, 2026

Modulating TLR/NF-KB and P53 signaling pathways to enhance interspecies chimerism between evolutionaryily distant species

Inventors: Jun Wu (Farmers Branch, TX); Canbin Zheng (Dallas, TX); Yingying Hu (Dallas, TX)
Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
C12N5/166C12N5/0604A01K2207/12A01K2207/15C12N2501/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12680084
App. No.
17/793,150
Granted
Jul 14, 2026
Kind
B2
Abstract

Disclosed herein are chimeric blastocysts, such as chimeric blastocysts derived from a host blastocyst from a first mammalian species and having donor pluripotent stem cells from a second mammalian species, wherein the donor pluripotent stem cells have reduced expression or reduced biological activity of one or more proteins in the TLR/NF-kB signaling pathway or the p53 pathway. Methods of preparing chimeric blastocysts and methods of obtaining mammalian organs and tissues are also provided.

Claims (11)

1 . A chimeric blastocyst, comprising:

(i) a host blastocyst from a first mammalian species, wherein the host blastocyst is an organogenesis disabled blastocyst comprising a genetic deficiency and wherein the first mammalian species is a rodent; and

(ii) donor pluripotent stem cells from a second mammalian species,

wherein the donor pluripotent stem cells have a homozygous disruption of one or more of p65 and MYD88, wherein said homozygous disruption leads to reduced expression or reduced biological activity of one or more of p65 and MYD88, and

wherein the second mammalian species is a human.

2 . The chimeric blastocyst of claim 1 , wherein the donor pluripotent stem cells comprise induced pluripotent stem cells.

3 . A method of preparing a chimeric blastocyst comprising:

injecting a host blastocyst from a first mammalian species, wherein the first mammalian species is a rodent, with donor pluripotent stem cells from a second mammalian species, wherein the second mammalian species is a human,

wherein the host blastocyst is an organogenesis disabled blastocyst comprising a genetic deficiency,

wherein the donor pluripotent stem cells have a homozygous disruption of one or more of p65 and MYD88, wherein said homozygous disruption leads to reduced expression or reduced biological activity of one or more of p65 and MYD88.

4 . The method of claim 3 , wherein the donor pluripotent stem cells comprise primed pluripotent stem cells.